Cystadrops (mercaptamine)
Orphan
- Region
- 🇪🇺 EU
- Active substance
- mercaptamine
- Company
- Recordati Rare Diseases
- Status
- Authorised
- Therapeutic area
- Cystinosis
- EU approval
- Wed 18 Jan 2017
- Designations
- Orphan
- Application
- EMEA/H/C/003769
- ATC
- S01XA21
- Official record
- www.ema.europa.eu
Indication
Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 6 months of age with cystinosis.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Procysbi Authorised · Chiesi Farmaceutici S.p.A
- 🇪🇺 Cystagon Authorised · Recordati Rare Diseases
- 🇪🇺 Dropcys Refused · Lucane Pharma
Follow Cystadrops
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.